The effect of Rho kinase inhibitor for the treatment of corneal endothelial dysfunction: the 2nd step

The effect of Rho kinase inhibitor for the treatment of corneal endothelial dysfunction: the 2nd step - The effect of Rho kinase inhibitor for the treatment of corneal endothelial dysfunction: the 2nd step

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003625

Enrollment

Registered

2010-05-17

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal endothelial dysfunction

Interventions

Administration of Rho kinase inhibitor eye drops (10mM Y-27632) 4 times daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Corneal endothelial cell density is lower than 2000cells/mm2 or not detectable by use of non-contact specular microscopy 2. Existence of visual disturbance or an assumption that visual disturbance will occur due to corneal endothelial dysfunction 3. Obtainment of prior written informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnant or breast-feeding women 2. Patients with a psychological disorder or who could not comprehend instructions from the physician 3. Other criteria deemed improper for inclusion

Design outcomes

Primary

Measure	Time frame
Corneal endothelial cell density	—

Secondary

Measure	Time frame
Visual acuity Corneal thickness Subjective visual function	—

Countries

Japan

Contacts

Public ContactNaoki Okumura

Kyoto Prefectural University of Medicine Department of Ophthalmology

nokumura@koto.kpu-m.ac.jp075-251-5578

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026